Phase III trials / Prof. Martin Edelman - Fox Chase Cancer Center, USA.

Format:

Video

Author/Creator:

Edelman, Martin J., author.

Language:

English

Subjects (All):

Cancer--Treatment.

Cancer.

Clinical trials.

Physical Description:

1 videorecording (31 mins., 45 sec.) : sound, color

Place of Publication:

London, England : Henry Stewart Talks Ltd, 2009.

System Details:

video file

Contents:

Introduction

Overview

Phase III trials: definition

Phase III trials are difficult

Adjuvant chemotherapy for NSCLC

Chemotherapy / radiation vs. radiation

Chemotherapy vs. observation

Statistical aspects of phase III studies: planning

Eligibility and treatment plan

Overall survival in total randomized population

Statistical aspects of phase III trials: execution

Statistical aspects of phase III trials: analysis

Why phase III trials? (1)

Example of phase II vs. phase III study results

SWOG 0023 study

S0023: overall survival

Why phase III trials? (2)

Bevacizumab - ECOG 4599 trial

Bevacizumab with chemotherapy: overall survival

Outcomes for elderly advanced NSCLC

Economic analysis: all else being equal

Quality of life and symptom control

Cisplatin+pemetrexed vs. cisplatin+gemcitabine

Overall survival

Overall survival in non-squamous patients

Why phase III trials? (3)

ECOG 4599 trial - advanced NSCLC

INT SCLC study of daily vs. BID radiotherapy

The future of phase III trials

The importance of phase II studies

Targeted populations

FLEX: 1st-line stage IIIB/IV NSCLC

N0723: predictive marker study design

An opportunity to utilize improved prognosis

How to use phase III data

JCOG trial: CDDP/CPT-11 vs. CDDP/VP-16

Overall survival in the U.S.A

Summary and conclusions.

Notes:

Description based on: online resource; title from PDF information screen (Henry Stewart Talks Biomedical and Life Sciences Collection, viewed April 5, 2024).

Retrieved April 10, 2024, from https://hstalks.com/bs/1116/.